Insulinoma-associated protein 1 (INSM1)

Insulinoma-associated protein 1 (INSM1) is a zinc finger transcription factor (with five zinc finger motifs), originally identified in a human insulinoma library, that plays a pivotal role in the development, maturation, and function of neuroendocrine cells[1][3]. INSM1 is expressed transiently during embryonic development in endocrine tissues such as brain, pancreas, adrenal gland, and intestine, and is largely silenced in adult tissues except in neuroendocrine tumors where its expression is reactivated to high levels[1][3]. It acts as a transcriptional repressor via interaction with chromatin-modifying enzymes (HDACs, LSD1) and co-factors (cyclin D1), regulating genes critical for neuroendocrine differentiation including NeuroD/β2 and insulin[1][5]. INSM1 is essential for endocrine cell differentiation in the pancreas and intestine, with gene knockout leading to impaired development of β-cells, islet cell maturation defects, and adrenal catecholamine deficiency[2]. Clinically, INSM1 is considered an important and reliable biomarker for the diagnosis of neuroendocrine tumors (including small cell lung cancer and insulinomas), and is being investigated as a specific promoter target for novel gene therapy or diagnostic probe development in neuroendocrine cancers[3][5]. Direct pharmacological modulation of INSM1 is challenging due to its nuclear localization and role as a transcription factor, but its utility as a biomarker and potential indirect target in cancer therapy is under investigation[3][5].

Other names

IA-1IA1Zinc finger protein IA-1insulinoma-associated 1INSM transcriptional repressor 1zinc finger protein IA-1

Transcriptional repression of neuroendocrine-specific genes via: - Recruitment of histone deacetylases (e.g., HDAC3, HDAC1/2) - Interaction with LSD1 (KDM1A), cyclin D1, and other chromatin-modifying proteins - Inhibition of NeuroD/β2 expression and other target genes[1][3][5]